Online inquiry

IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14249MR)

This product GTTS-WQ14249MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ERBB3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001005915.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065
UniProt ID P21860
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14249MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ308MR IVTScrip™ mRNA-Anti-IGF1R, 19D12(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 19D12
GTTS-WQ7273MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FP3 protein
GTTS-WQ10946MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MBG-453
GTTS-WQ7167MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
GTTS-WQ10851MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA M9346A
GTTS-WQ12851MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OPN-305
GTTS-WQ1578MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-083
GTTS-WQ8651MR IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HuMax-CD38
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW